Long non-coding RNA mediated drug resistance in breast cancer. (July 2022)

• Record Type: Journal Article
• Authors: Singh, Deepshikha; Assaraf, Yehuda G.; Gacche, Rajesh N.
• Is Part Of: Drug resistance updates. Volume 63(2022)
• Publication Date: 2022-07
• Subjects: LncRNA Long non-coding RNA -- BC Breast cancer -- ncRNA Non-coding RNA -- miRNA micro RNA -- circRNA circular RNA -- HER2 Human epidermal growth factor receptor 2 -- AGAP2-AS1 AGAP2 Antisense RNA 1 -- CPT1 Carnitine palmitoyltransferase 1 -- FAO Fatty Acid oxidation -- TINCR Terminal differentiation-induced non-coding RNA -- ZNF649-AS1 ZNF649 Antisense RNA1 -- PTBP1 Polypyrimidine tract binding protein1 -- GAS5 Growth arrest-specific transcript 5 -- PTEN Phosphatase and tensin homologs -- lnc-ATB LncRNA Activated By TGF-Beta -- ZEB1 Zinc finger E-box-binding homeobox 1 -- SNHG14 Small Nucleolar RNA Host Gene 14 -- BAX Bcl-2-associated X -- Bcl B-cell lymphoma 2 -- AFAP1-AS1 AFAP1 Antisense RNA 1 -- TAM Tamoxifen -- MAPK Mitogen-activated protein kinase -- ERK Extracellular signal-regulated kinase -- UCA1 Urothelial Cancer Associated 1 -- CDK1 Cyclin-dependent kinase 1 -- CASC2 Cancer susceptibility candidate 2 -- TNBC Triple negative breast cancer -- LINC-PINT Long Intergenic Non-Protein Coding RNA-p53 Induced Transcript -- MALAT1 Metastasis associated lung adenocarcinoma transcript 1 -- XIST X-inactive specific transcript -- TMPO-AS1 TMPO Antisense RNA 1 -- PVT1 Plasmacytoma variant translocation 1 -- Keap1 Kelch-like ECH-associated protein 1 -- Nrf2 Nuclear factor erythroid 2 like 2 -- NEAT1 Nuclear Enriched Abundant Transcript 1 -- HOTAIR HOX antisense intergenic RNA -- ROR Regulator of reprogramming -- BORG BMP/OP-Responsive Gene -- EGOT Eosinophil granule ontogeny transcript -- BDNF-AS Brain Derived Neurotrophic Factor Antisense RNA -- RNH1 Ribonuclease inhibitor 1 -- TRIM-21 Tripartite motif containing-21 -- HOXA1 Homeobox A1 -- LINP1 LncRNA In Non-Homologous End Joining Pathway1 -- SAHH S-adenosylhomocysteine hydrolase -- H19 H19 Imprinted Maternally Expressed Transcript -- DNMT3B DNA Methyltransferase 3 Beta -- CYTOR Cytoskeleton regulator RNA -- ce-RNA Competitive endogenous RNA -- SRF Serum response factor -- ATXN8OS Ataxin 8 opposite strand -- VASP Vasodilator-stimulated phosphoprotein -- PTX Paclitaxel -- FTH1P3 Ferritin heavy chain 1 pseudogene 3 -- MRP Multidrug resistance-associated proteins -- BCRP Breast Cancer Resistance Protein -- MDR1 Multidrug resistance 1 -- NONO Non-POU Domain Containing Octamer Binding -- RBP RNA-binding protein -- MEG3 Maternally expressed 3 -- MTDH Metadherin -- 5-FU 5-Fluorouracil -- ARF6 ADP-ribosylation factor 6 -- CSC Cancer stem cells -- EMT Epithelial-mesenchymal transition -- ABCB1 ATP Binding Cassette Subfamily B Member 1 -- PTEN Phosphatase and tensin homolog -- GATA-3 GATA binding protein 3 -- STAT3 Signal Transducer And Activator Of Transcription 3 -- CDKL5 Cyclin-Dependent Kinase-Like 5 -- PI3K Phosphoinositide 3-kinases -- ANCR antidifferentiation ncRNA -- Tax Taxifolin -- ceRNA competitive endogenous RNA -- LINC Long Intergenic Non-Protein Coding RNA -- HORMAD1 HORMA Domain Containing 1 -- PTENP1 Phosphatase and Tensin Homolog Pseudogene 1 -- lncTALAM1 TALAM1 Transcript -- MALAT1 Metastasis-associated lung adenocarcinoma transcript 1 -- SWI/SNF SWItch/Sucrose Non-Fermentable -- DICER1, Dicer 1, Ribonuclease III; Long non-coding RNAs -- Breast cancer -- Anti-breast cancer drugs -- Drug resistance mechanisms; Drug resistance in cancer cells -- Periodicals; Cancer -- Chemotherapy -- Periodicals; 616.994061
• DOI: 10.1016/j.drup.2022.100851
• Languages: English
• ISSNs: 1368-7646

Abstract

Abstract: Breast cancer is one of the most prevalent cancers in women and a leading cause of mortality. As per the GLOBCAN report of 2021, breast cancer has surpassed lung cancer which until recently was the most commonly diagnosed cancer. Despite significant efforts to improve early detection and therapeutic efficacy of breast cancer, the frequent emergence of drug resistance remains the predominant basis for the poor prognosis of cancer patients harboring various malignancies. Long non-coding RNA (lncRNAs) are known to affect a variety of components of genome function, including epigenetics, gene transcription, splicing, translation, as well as many central biological processes like cell cycle progression, cell differentiation, development, and pluripotency. LncRNAs are dysregulated in various malignancies and interact with a multitude of RNAs and proteins to impact drug resistance. LncRNAs regulate chemoresistance in cancer by employing an assortment of molecular mechanisms including multidrug efflux, suppression of apoptosis, DNA damage response, epigenetic alterations, as well as functioning as competitive endogenous RNA. When combined with other regulatory mechanisms, these pathways form a complex orchestration of signaling that ultimately lead to chemoresistance. The current review delves into the role of lncRNAs in inducing drug resistance to conventional therapeutic anti-cancer drugs used for the treatment of breast cancer. We propose that lncRNAs that provoke drug resistance could be used to develop new targeted and tailored therapeutics providing a novel approach to introduce promising personalized treatment modalities to overcome chemoresistance in breast cancer patients. Hence, lncRNAs that drive anticancer drug resistance can be potentially explored as biomarkers of disease prognosis and may provide unique opportunities to circumvent chemoresistance in breast cancer patients.